REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic
gastro-oesophageal adenocarcinomas: A randomized phase II trial
ANNÉE
2019
AUTEURS
Samalin E, Turpin A, Khemissa F, Zaanan A, Ben Abdelghani M, Senellart H, Gilabert M, Evesque L, Dahan L, Sefrioui D, Bouche O, De La Fouchadiere C, Hennequin A, Monard L, Gourgou S, Lopez A
CONGRÈS/REVUE
ESMO GI
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES